Search results for "biomarkers."

showing 10 items of 1947 documents

Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions.

2013

Thyroid cancer is the most common endocrine malignancy. However, more than 90% of thyroid nodules are benign. It remains unclear whether thyroid carcinoma arises from preexisting benign nodules. Metabolomics can provide valuable and comprehensive information about low molecular weight compounds present in living systems and further our understanding of the biology regulating pathological processes. Herein, we applied ¹H NMR-based metabolic profiling to identify the metabolites present in aqueous tissue extracts of healthy thyroid tissue (H), non-neoplastic nodules (NN), follicular adenomas (FA) and malignant thyroid cancer (TC) as an alternative way of investigating cancer lesions. Multivar…

Adenomaendocrine systemMagnetic Resonance Spectroscopyendocrine system diseaseslcsh:Rlcsh:MedicineMultivariate AnalysisBiomarkers TumorHumansMetabolomicslcsh:QThyroid Neoplasmslcsh:ScienceResearch ArticlePloS one
researchProduct

Histomorphological evaluation, cell proliferation and endothelial immunostaining in oral and maxillofacial myofibroblastic lesions.

2022

Myofibroblasts (MF) are mesenchymal cells with features of both fibroblasts and smooth muscle cells. Although these are usually reactive cells, they can lead to myofibroblastic tumors that may share clinical and histomorphological characteristics but with different prognosis. The aim of this study is to perform a histomorphological evaluation as well as to compare and evaluate two different cell proliferation immunomarkers and two endothelial markers in a group of oral and maxillofacial myofibroblastic lesions (MFL). Cross-sectional and retrospective study. Demographic, clinical, histomorphological and immunohistochemical characteristics of 39 cases of MFL were analyzed. Immunohistochemical…

Adolescentorthognathic surgeryImmunohistochemistryGranuloma Plasma CellCross-Sectional StudiesOtorhinolaryngologysystematic reviewBiomarkers TumorHumansSurgeryvirtual planningFemaleMyofibroblastsGeneral DentistryUNESCO:CIENCIAS MÉDICASBiomarkersRetrospective StudiesCell ProliferationMedicina oral, patologia oral y cirugia bucal
researchProduct

The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer

2019

There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database.Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted …

Adult0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSocio-culturaleBreast NeoplasmsLapatinibTreatment experiencedRadiosurgerySRS03 medical and health sciences0302 clinical medicineBreast cancerTrastuzumabInternal medicineHER2 Positive Breast CancerBiomarkers TumormedicineHumansAgedRetrospective Studiesbusiness.industryLapatinibTrastuzumabMiddle AgedWBRTPrognosismedicine.diseaseCombined Modality TherapyConfidence intervalSurvival RateRadiation therapyLapatinib SRS Surgery Trastuzumab WBRT030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisLapatinib; SRS; Surgery; Trastuzumab; WBRTSurgeryFemaleNeoplasm Recurrence LocalbusinessFollow-Up Studiesmedicine.drugClinical Breast Cancer
researchProduct

Relationship between apoptosis and survival molecules in human cumulus cells as markers of oocyte competence

2017

SummaryTo select from a single patient the best oocytes able to reach the blastocyst stage, we searched for valuable markers for oocytes competence. We evaluated the DNA fragmentation index (DFI) and the level of some survival molecules, such as AKT, pAKT and pERK1/2, in individual cumulus cell–oocyte complexes (COC). The study included normo-responder women. The average age of the patients was 34.3. DFI in cumulus cells was evaluated using the terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labelling (TUNEL) assayin situ. AKT, pAKT and pERK1/2 were measured by immunological assay and densitometric analysis of fluorescent signals using NIS-Elements BR 3.10 image software. Statisti…

Adult0301 basic medicineCell SurvivalApoptosisDNA FragmentationBiologyMolecular markerAndrology03 medical and health sciences0302 clinical medicineOocyte competencemedicineHumansProspective StudiesBlastocystPhosphorylationSettore BIO/06 - Anatomia Comparata E CitologiaExtracellular Signal-Regulated MAP KinasesCells CulturedCumulus Cells030219 obstetrics & reproductive medicineTUNEL assayApoptosiEmbryoCell BiologyOocyteIn vitroCell biology030104 developmental biologymedicine.anatomical_structureHuman cumulus cellTerminal deoxynucleotidyl transferaseApoptosisSurvival moleculeOocytesDNA fragmentationFemaleProto-Oncogene Proteins c-aktBiomarkersDevelopmental Biology
researchProduct

Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy

2018

Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance. Patients and Methods Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected ( BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resist…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGenes BRCA2Genes BRCA1Phases of clinical researchAntineoplastic AgentsBreast NeoplasmsHeterocyclic Compounds 4 or More RingsMice03 medical and health sciences0302 clinical medicineGermline mutationInternal medicineBiomarkers TumorClinical endpointAnimalsHumansMedicineProgression-free survivalGerm-Line MutationAgedDose-Response Relationship DrugErratabusiness.industryMiddle Agedmedicine.diseaseXenograft Model Antitumor AssaysMetastatic breast cancerProgression-Free SurvivalClinical trial030104 developmental biologyOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisBiomarker (medicine)FemalebusinessCarbolinesJournal of Clinical Oncology
researchProduct

Congenital undifferentiated sarcoma associated to BCOR-CCNB3 gene fusion

2017

Small round cell sarcomas are aggressive bone and soft tissue tumors that predominantly affect children and young adults. A new group of sarcomas with a recurrent BCOR-CCNB3 gene fusion has been recently identified in previously unclassifiable small round cell sarcomas. BCOR-CCNB3 sarcomas share clinical and pathologic similarities with Ewing sarcoma, but show a stronger male predilection and less aggressiveness, as well as distinct gene expression profiling and pangenomic SNP array analyses. We report the unusual case of a congenital BCOR-CCNB3 retroperitoneal sarcoma in a female born at 34th gestational week, which was diagnosed in necropsy after 21hours of life. Immunohistochemical analy…

Adult0301 basic medicinePathologymedicine.medical_specialtyOncogene Proteins FusionTumor suppressor geneCD99Soft Tissue NeoplasmsCyclin BBiologyPathology and Forensic MedicineDiagnosis DifferentialFusion gene03 medical and health sciences0302 clinical medicineProto-Oncogene ProteinsBiomarkers TumormedicineHumansSMARCB1SarcomaCell Biologymedicine.diseaseRepressor ProteinsGene expression profiling030104 developmental biology030220 oncology & carcinogenesisCancer researchImmunohistochemistryFemaleSarcomaGene FusionSNP arrayPathology - Research and Practice
researchProduct

Diagnostic problems and postnatal follow-up in congenital toxoplasmosis

2007

Aim. In order to assess the consequences of different clinica] approaches in the prenata] management of congenital toxoplasmosis, we retrospectively reviewed 58 pregnant women with Toxoplasma seroconversion and prospec­ tively enrolled their 59 infants, referred to us from 1999 to 2004. Metbods. Data on clinica!, laboratocy and de­ mographic characteristics of the pregnant women were collected. Their children were entered intoa 48-month follow-up progcamme in which clinica , instrumental, ophthalmo­ logic and serologic evaluations were carried out at birth, at 1, 3, 6, 9, 15, 18, 24, 36 and at 48 months of life. Paediatric treatment with Spiramycin alone or alternated with Pyrime­ thamine-S…

AdultAdolescentSettore MED/17 - Malattie InfettiveAntiprotozoal AgentsSulfadiazinePolymerase Chain ReactionToxoplasmosis CongenitalAntimalarialsPregnancyAnimalsHumansProspective StudiesSicilyRetrospective StudiesInfantToxoplasmosis Diagnostic stepsInfectious Disease Transmission VerticalPyrimethamineTreatment OutcomeImmunoglobulin MImmunoglobulin GPregnancy Complications ParasiticAmniocentesisCoccidiostatsDrug Therapy CombinationFemalePregnancy TrimestersBiomarkersFollow-Up Studies
researchProduct

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

2017

Abstract Background Transarterial chemoembolisation is the standard of care for intermediate stage (BCLC B) hepatocellular carcinoma, but it is challenging to decide when to repeat or stop treatment. Here we performed the first external validation of the SNACOR (tumour Size and Number, baseline Alpha-fetoprotein, Child-Pugh and Objective radiological Response) risk prediction model. Methods A total of 1030 patients with hepatocellular carcinoma underwent transarterial chemoembolisation at our tertiary referral centre from January 2000 to December 2016. We determined the following variables that were needed to calculate the SNACOR at baseline: tumour size and number, alpha-fetoprotein level,…

AdultAged 80 and overMaleCarcinoma HepatocellularHepatocellular carcinomaLiver Neoplasms610 MedizinKaplan-Meier EstimateSNACORMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282Magnetic Resonance ImagingTreatment OutcomeTransarterial chemoembolisation610 Medical sciencesBiomarkers TumorHumansFemaleChemoembolization TherapeuticTomography X-Ray ComputedAgedNeoplasm StagingResearch Article
researchProduct

Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

2021

AbstractThere is evidence of reduced SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies. We hypothesized that tumor and treatment-related immunosuppression can be depicted in peripheral blood, and that immune profiling prior to vaccination can help predict immunogenicity. We performed a comprehensive immunological characterization of 83 hematological patients before vaccination and measured IgM, IgG, and IgA antibody response to four viral antigens at day +7 after second-dose COVID-19 vaccination using multidimensional and computational flow cytometry. Health care practitioners of similar age were the control group (n = 102). Forty-four out of 59 immune cell types …

AdultAged 80 and overMaleHaematological cancerCOVID-19 VaccinesSARS-CoV-2COVID-19Vaccine EfficacyNeoplasms. Tumors. Oncology. Including cancer and carcinogenslymphomaHematologyMiddle Agedhematologic malignancieArticleImmunocompromised HostmyelomaOncologyHematologic NeoplasmsHumansTumour immunologyFemaleSars-cov-BiomarkersRC254-282AgedBlood Cancer Journal
researchProduct

Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocard…

2007

N-terminal pro-b-type natriuretic peptide (NT pro-BNP) is a neurohormone synthesized predominantly in ventricular myocardium. In patients with symptoms of heart failure, elevation in NT pro-BNP accurately identifies ventricular dysfunction. However, NT pro-BNP levels are not specific for ventricular dysfunction in patients who do not have overt symptoms of heart failure, suggesting that other cardiac processes such as myocardial ischemia may also cause elevation in NT pro-BNP. The study was aimed to determine whether NT pro-BNP elevations are associated with myocardial ischemia.One hundred and thirty patients (104 males, 26 females, mean age 61+12 years), with ST elevation acute myocardial …

AdultAged 80 and overMaleTomography Emission-Computed Single-PhotonMyocardial InfarctionMyocardial IschemiaOrganotechnetium CompoundsMiddle AgedSensitivity and SpecificityPeptide FragmentsElectrocardiographyLogistic ModelsOrganophosphorus CompoundsROC CurvePredictive Value of TestsNatriuretic Peptide BrainExercise TestOdds RatioHumansFemaleRadiopharmaceuticalsBiomarkersAgedEchocardiography StressRetrospective Studies
researchProduct